Investor Presentaiton

ENHERTU® Primary analysis of DESTINY-PanTumor02 study TLR from the primary analysis was acquired in Jul 2023 Daiichi-Sankyo Interim Analysis Primary Analysis 276 Cervical cancer 576 Endometrial cancer 276 Ovarian cancer T-DXd 5.4 mg/kg Biliary tract cancer q3w Pancreatic cancer Bladder cancer Other tumorsa Primary endpoint: confirmed ORR (investigator) ➤ Secondary endpoint: DoR, DCR, PFS, OS, safety Reported at ASCO 2023 Continued to show durable responses for ORR and DoR ■ Demonstrated clinically meaningful PFS and OS results ■ILD rates and severity were consistent with those observed in other trials of ENHERTU. ■Data will be presented at an upcoming medical meeting ■Discussions with health authorities are ongoing Obtained in Jul 2023 a Patients with tumors that express HER2, excluding tumors in the tumor-specific cohorts, and breast cancer, non-small cell lung cancer, gastric cancer, and colorectal cancer. ASCO: American Society of Clinical Oncology, DCR: disease control rate, DoR: duration of response, ORR: objective response rate, OS: overall survival, PFS: progression-free survival, q3w: every 3 weeks, T-DXd: trastuzumab deruxtecan 20 20

View entire presentation